CytRx Corporation(CYTR) shares saw a recent bid of $0.61 and 17.6M shares have exchanged hands in the recent trading session, yielding a 21.76% gain over the past week. The stock price increased 20.72% or $-0.11 versus $0.50 at the end of the prior session. This change led market cap to move at $88.98M, putting the price -81.42% below the 52-week high and 68.64% above the 52-week low. The company’s stock has a normal trading capacity of 4.64M shares while the relative volume is 3.80.
To stay one step ahead we extended our research by comparing different price targets. And it remains to be seen which target price CYTR can achieve without sacrificing much as the company is holding a -78.02% fall for the past twelve months.
By historical standards, CytRx Corporation remains a cheap stock. For now, CytRx Corporation is the toast of Wall Street as its ABR stands at 2.00 with 0 out of 1 analysts rating the stock a buy. Over the short term, some market observers may have noticed that CytRx Corporation has a 15.78% short float with 15 days to cover. It becomes significant when you consider how many shares are shorted versus the average daily volume, means how many days to cover those short shares at that volume. CytRx Corporation has far performed well this year, with the share price up 63.57% since January. Over the past 2 quarters, the stock is up 5.06%, compared with a gain of nearly 45.65% for 3 months and about -24.44% for the past 30 days.
Last time, the company shocked Wall Street by reporting EPS of $-0.06, smashing the consensus of $-0.11 per share. Revenue for the quarter also killed consensus, coming in at $0M, compared to the consensus of 0M. Nonetheless, from here on out, earnings per share forecasts for the current quarter are $-0.50. The company is expected to report EPS as high as $-0.50 and as low as $-0.50 per share. On the other side, sales forecasts for the current quarter are $11.42M. The stock is expected to report revenue as high as $11.42M and as low as $11.42M per share. Similarly, full-year sales forecasts have ranged between $-0.5M and $-0.5M. The mean revenue estimate is $-0.5M.
Over the last 5 years, CytRx Corporation has averaged a 4.80% YoY EPS growth rate and a -4.40% revenue growth rate. Analysts are expecting EPS growth rates to be at 34.90% this quarter and EPS estimate for next year reflect a 18.00% growth rate.
Sell-side analysts also have something to say about this company. FBR Capital analysts stated on 12/07/2016 that they maintained their Outperform rating. Jefferies analysts stated on 07/01/2016 that they launched coverage on this stock with Hold rating. Oppenheimer analysts stated on 17/04/2015 that they launched coverage on this stock with Outperform rating. Aegis Capital analysts stated on 23/01/2014 that they maintained their Buy rating.